Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharp and Dohme launches antibiotic Zerbaxa in UK

Merck Sharp and Dohme launches antibiotic Zerbaxa in UK

24th November 2015

Merck Sharp and Dohme has announced the UK launch of Zerbaxa, a new ceftolozane/tazobactam intravenous antibiotic product.

The new antibiotic is designed for the treatment of complicated intra-abdominal infections, acute pyelonephritis and complicated urinary tract infections in hospital settings. It is administered every eight hours, with treatment usually lasting four to 14 days.

Zerbaxa represents an alternative to carbapenems, the current standard of care, which have been linked to the emergence of carbapenem-resistant bacteria contributing to global antimicrobial resistance.

Two pivotal phase III clinical trials have demonstrated the non-inferiority of the new antibiotic to an established comparator.

Mike Nally, managing director of Merck Sharp and Dohme for the UK and Ireland, said the company "continues to advocate for improvements in regulatory guidance and financial incentives to support and accelerate innovation in the development of new antimicrobials, services and solutions".

The company acquire the rights to Zerbaxa as part of its $9.5 billion (6.28 billion pounds) acquisition of Cubist Pharmaceuticals earlier this year.ADNFCR-8000103-ID-801806461-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.